Table 2.
No. | Author | Enrolled cases | Disease type causing FUO (%) | Reported or calculable results | Redefining | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Infection | NIID | Malignancy | Miscellaneous | Undiagnosed | Sensitivity | Specificity | PPV | Accuracy | DY | TP/FN/FP/TN | TP/FN/FP/TN | |||
1 | Keidar et al. [59] | 48 | 19 | 33 | 6 | 2 | 40 | 100 | 81 | 81 | 90 | 46 | 22/0/5/21 | 22/7/4/15 |
2 | Balink et al. [60] | 68 | 37 | 21 | 3 | 4 | 35 | 100 | 90 | 93 | 96 | 56 | 38/6/3/21 | 38/6/3/21 |
3 | Federici et al. [61] | 14 | 29 | 36 | 7 | 0 | 29 | 70 | 75 | 88 | 71 | 50 | 7/3/1/3 | 7/3/1/3 |
4 | Ferda et al. [62] | 48 | 38 | 38 | 17 | 0 | 8 | 98 | 75 | 98 | 96 | 90 | 43/1/1/3 | 43/1/1/3 |
5 | Kei et al. [63] | 12 | 33 | 8 | 17 | 0 | 42 | 71 | 60 | 71 | 67 | 42 | 5/2/2/3 | 5/2/2/3 |
6 | Sheng et al. [64] | 48 | 31 | 19 | 25 | 0 | 25 | 89 | 33 | 80 | 75 | 67 | 32/4/8/4 | 32/4/8/4 |
7 | Pelosi et al. [65] | 24 | 25 | 29 | 13 | 4 | 29 | 65 | 71 | 85 | 67 | 46 | 11/11/2/0 | 11/6/1/6 |
8 | Ergül et al. [66] | 24 | 13 | 13 | 21 | 8 | 46 | 92 | 45 | 63 | 79 | 50 | 12/0/7/5 | 12/1/6/5 |
9 | Kim et al. [67] | 48 | 29 | 4 | 15 | 38 | 15 | 89 | 20 | 61 | 60 | 52 | 25/3/16/4 | 25/16/3/4 |
10 | Crouzet et al. [68] | 79 | 29 | 25 | 15 | 8 | 23 | 98 | 87 | 96 | 95 | 74 | 45/19/2/13 | Unclassifiable |
11 | Pedersen et al. [69] | 22 | 5 | 41 | 14 | 0 | 41 | 67 | 71 | 83 | 68 | 45 | 10/5/2/5 | 10/4/2/6 |
12 | Nakayo et al. [70] | 20 | 15 | 15 | 25 | 0 | 45 | 79 | 83 | 92 | 80 | 55 | 11/3/1/5 | 12/8/0/0 |
13 | Manohar et al. [71] | 103 | 30 | 21 | 13 | 3 | 33 | 90 | 97 | 98 | 92 | 60 | 62/7/1/3 | 62/7/1/3 |
14 | Tokmak et al. [72] | 25 | 32 | 40 | 12 | 0 | 16 | 94 | 80 | 94 | 90 | 71 | 15/1/1/4 | 15/6/1/3 |
15 | Gafter-Gvili et al. [73] | 112 | 44 | 15 | 13 | 2 | 26 | 72 | 58 | 75 | 65 | 46 | 52/20/17/23 | 51/32/9/20 |
16 | Bucher-Olsen et al. [74] | 57 | 51 | 21 | 7 | 7 | 14 | 93 | 60 | 68 | 75 | 44 | 25/2/12/18 | 25/24/3/5 |
17 | Singh et al. [75] | 47 | 19 | 21 | 11 | 2 | 47 | 82 | 32 | 51 | 55 | 38 | 18/4/17/8 | 18/7/14/8 |
18 | Pereira et al. [76] | 76 | 21 | 12 | 22 | 5 | 40 | 77 | 31 | 61 | 58 | 45 | 32/14/0/5 | 43/3/10/20 |
19 | Hung et al. [77] | 58 | 40 | 19 | 17 | 3 | 21 | 79 | 56 | 83 | 72 | 57 | 33/9/7/9 | 33/13/4/8 |
20 | García-Vicente et al. [78] | 67 | 31 | 49 | 6 | 1 | 12 | 84 | 31 | 62 | 61 | 48 | 32/6/20/9 | 32/26/0/9 |
21 | Okuyucu et al. [79] | 74 | 26 | 45 | 9 | 5 | 14 | 75 | 69 | 92 | 74 | 62 | 46/15/4/9 | 46/19/0/9 |
22 | Georga et al. [80] | 50 | 40 | 22 | 16 | 0 | 22 | 95 | 50 | 84 | 84 | 72 | 36/2/6/6 | 36/4/4/6 |
23 | Das et al. [81] | 43 | 23 | 37 | 9 | 5 | 26 | 77 | 33 | 83 | 51 | 47 | 20/6/4/2 | 20/12/11/0 |
24 | Letertre et al. [82] | 39 | 23 | 44 | 8 | 5 | 21 | 85 | 37 | 58 | 62 | 44 | 17/3/12/7 | 17/3/12/7 |
25 | Buchritis et al. [83] | 303 | 37 | 17 | 18 | 0 | 28 | 89 | 82 | 87 | 86 | 52 | 158/20/23/102 | 158/20/23/102 |
26 | Mahajna et al. [84] | 128 | 48 | 16 | 9 | 1 | 26 | 70 | 37 | 70 | 67 | 47 | 60/16/26/26 | 60/33/9/26 |
NIID noninfectious inflammatory disease, PPV positive predictive value, DY diagnostic yield, TP true positive, FN false negative, FP false positive, TN true negative